Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Metastasis02:30

Metastasis

5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemical and sensory effects of macro-oxygenation and air sparging coupled with oxidation-reduction potential (ORP) monitoring in Syrah wines.

Food chemistry: X·2025
Same author

Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.

Journal of bone oncology·2025
Same author

Mapping the Metastatic Landscape: A Population-Based Cohort Study for Prognostic Insights Into Newly Diagnosed Stage IV Breast Cancer Cases.

Cancer innovation·2025
Same author

Leukoaraiosis does not impact motor outcomes in Parkinson's patients post deep brain stimulation.

Clinical parkinsonism & related disorders·2025
Same author

The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexity.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Validating the underpinnings of water corticosterone measurement for aquatic amphibians.

F1000Research·2025
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Sep 3, 2025

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.7K

Bone-Targeted Agents and Metastasis Prevention.

Robert Coleman1

  • 1Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK.

Cancers
|July 27, 2022
PubMed
Summary
This summary is machine-generated.

Adjuvant bisphosphonates significantly reduce bone recurrence and breast cancer mortality in postmenopausal women with early breast cancer. Benefits were not observed in premenopausal women, highlighting the importance of menopausal status for treatment efficacy.

Keywords:
adjuvant therapybiomarkersbisphosphonatesbone-targeted treatmentsbreast cancerdenosumab

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

5.3K
Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.3K

Related Experiment Videos

Last Updated: Sep 3, 2025

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.7K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

5.3K
Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metastasis Research

Background:

  • Bone-targeted treatments, including bisphosphonates and denosumab, are crucial in managing metastatic breast cancer.
  • The impact of these agents on bone physiology and the metastatic process is extensively studied.
  • Previous adjuvant trials with bisphosphonates in early breast cancer yielded variable outcomes, suggesting patient-specific factors influence efficacy.

Purpose of the Study:

  • To investigate the influence of patient age and menopausal status on the efficacy of adjuvant bisphosphonates in early breast cancer.
  • To analyze individual patient data from all available randomized trials to confirm or refute observed variable outcomes.
  • To guide clinical practice regarding the use of bone-targeted agents in breast cancer adjuvant therapy.

Main Methods:

  • A comprehensive meta-analysis of individual patient data from all relevant randomized trials was conducted.
  • The analysis specifically examined outcomes based on menopausal status (premenopausal vs. postmenopausal women).
  • Disease recurrence and breast cancer mortality were the primary endpoints assessed.

Main Results:

  • Adjuvant bisphosphonates demonstrated no significant benefit in premenopausal women.
  • A highly significant improvement in bone recurrence (RR = 0.72) and breast cancer mortality (RR = 0.82) was observed in 11,767 postmenopausal women.
  • These findings support the efficacy of bisphosphonates in a specific patient subgroup.

Conclusions:

  • Clinical guidelines should incorporate adjuvant bisphosphonates for osteoclast inhibition in routine care for eligible postmenopausal women.
  • The differing outcomes between bisphosphonates and denosumab suggest potential "off-target" effects of bisphosphonates on immune function may be critical.
  • Further research into predictive biomarkers, such as MAF, is warranted to identify patients who can benefit from bisphosphonate therapy.